We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX - Free Report) will report quarterly earnings of $4.85 per share in its upcoming release, pointing to a year-over-year increase of 7.3%. It is anticipated that revenues will amount to $3.23 billion, exhibiting an increase of 8.8% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Vertex metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Revenues- Product revenues, net' reaching $3.24 billion. The estimate points to a change of +10.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues by Product- Other product revenues' should arrive at $133.50 million. The estimate indicates a change of -43.5% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues by Product- Trikafta/Kaftrio' of $2.45 billion. The estimate points to a change of -3.9% from the year-ago quarter.
Analysts forecast 'Revenues by Product- ALYFTREK' to reach $529.27 million. The estimate indicates a change of +237.5% from the prior-year quarter.
Over the past month, shares of Vertex have returned -1.3% versus the Zacks S&P 500 composite's +1.9% change. Currently, VRTX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX - Free Report) will report quarterly earnings of $4.85 per share in its upcoming release, pointing to a year-over-year increase of 7.3%. It is anticipated that revenues will amount to $3.23 billion, exhibiting an increase of 8.8% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Vertex metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Revenues- Product revenues, net' reaching $3.24 billion. The estimate points to a change of +10.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues by Product- Other product revenues' should arrive at $133.50 million. The estimate indicates a change of -43.5% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues by Product- Trikafta/Kaftrio' of $2.45 billion. The estimate points to a change of -3.9% from the year-ago quarter.
Analysts forecast 'Revenues by Product- ALYFTREK' to reach $529.27 million. The estimate indicates a change of +237.5% from the prior-year quarter.
View all Key Company Metrics for Vertex here>>>Over the past month, shares of Vertex have returned -1.3% versus the Zacks S&P 500 composite's +1.9% change. Currently, VRTX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .